Hepalatide - Shanghai HEP Pharmaceutical
Alternative Names: L 47Latest Information Update: 06 Jan 2026
At a glance
- Originator Shanghai HEP Pharmaceutical
- Class Antihyperglycaemics; Antivirals; Peptides
- Mechanism of Action Sodium-bile acid cotransporter modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B; Hepatitis D
- No development reported Diabetes mellitus
Most Recent Events
- 30 Dec 2025 Shanghai HEP Pharmaceutical plans a phase-III trial for Hepatitis D in China (SC), (NCT07309380)
- 28 Jul 2025 No recent reports of development identified for preclinical development in Diabetes-mellitus in China (SC)
- 07 May 2025 Efficacy and adverse event data from phase II trial in Hepatitis B presented at the European Association for the Study of the Liver Congress 2025 (EASL-2025)